Evidence map›Paper›PMID 41756880›Full record

ArticlebioRxiv : the preprint server for biology2026

Mechanism of Gating and Isoform-Specific Inhibition in Renal CLC Chloride Channels.

Chih-Ta Chien, Briana L Sobecks, Alexander S Powers, Jürgen Kreiter, Anindita Das, Chloe N Barry, Muyuan Chen, Andrew Hinman, Camille F Petrakian, Natasa Trifkovic and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Chih-Ta Chienco-first authors.ORCID 0000-0002-7796-0937
Briana L Sobecksco-first authors.ORCID 0000-0003-2086-8598
Alexander S Powersco-first authors.
Jürgen KreiterDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0001-5877-762X
Anindita DasDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0003-2329-5430
Chloe N BarryInnovative Medicines Accelerator, Stanford University, Stanford, CA 94305.
Muyuan ChenDivision of CryoEM and Bioimaging, SSRL, SLAC National Accelerator Laboratory, Stanford University, Menlo Park 94025.ORCID 0000-0003-1311-7868
Andrew HinmanInnovative Medicines Accelerator, Stanford University, Stanford, CA 94305.
Camille F PetrakianDepartment of Computer Science, Stanford University, Stanford, CA 94305.
Natasa TrifkovicDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.
Brianna WilliamsInnovative Medicines Accelerator, Stanford University, Stanford, CA 94305.
Chase A P WoodDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0003-4950-3533
Mengyuan XuDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0002-1734-4163
Ron O DrorDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305.ORCID 0000-0002-6418-2793
Wah ChiuDepartment of Bioengineering, Stanford University, Stanford, CA 94305.ORCID 0000-0002-8910-3078
Merritt MadukeDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0001-7787-306X

Funding

The Stanford-SLAC CryoEM CenterR24GM154186 · NIGMS · STANFORD UNIVERSITY · PI Wah Chiu, BRITT HEDMAN · 2024 to 2026
$19.3M
Structure-based strategy for developing inhibitors of the kidney chloride channel CLC-KaR01DK128881 · NIDDK · STANFORD UNIVERSITY · PI MADUKE, MERRITT C · 2021 to 2025
$3.1M
Comprehensive analysis of macromolecule structural variability in CryoEM/CryoETR01GM150905 · NIGMS · STANFORD UNIVERSITY · PI Muyuan Chen · 2023 to 2026
$1.5M
NIDDK NIH HHS R01 DK128881NIGMS NIH HHS R01 GM150905NIGMS NIH HHS R24 GM154186
6 · The paper itself

Abstract

Hyponatremia is a prevalent disorder marked by excess water retention and substantial morbidity, motivating interest in the CLC-Ka chloride channel as a therapeutic target. Selectively inhibiting CLC-Ka without affecting the closely related CLC-Kb is essential for preventing serious side effects. However, developing isoform-selective inhibitors has been challenging because most small molecules do not distinguish between CLC-Ka and CLC-Kb, and the basis for selectivity in the few known exceptions remains unclear. The small molecule BIM1 preferentially inhibits CLC-Ka over CLC-Kb, providing an opportunity to dissect isoform-specific pharmacology. To investigate this mechanism, we determined cryo-EM structures of BIM1 and BIM15, a related nonselective analog, bound to a CLC-K variant engineered to match the human CLC-Ka binding pocket. Structural and computational analyses reveal that inhibition and isoform selectivity are anchored by interactions with a conserved lysine, with surrounding binding-site residues subtly tuning the local electrostatic environment to promote or disfavor these contacts. These analyses further identify a dynamic extracellular loop that intermittently occludes the access pathway, indicating its role as a gate for ions and inhibitors. BIM15 engages this gating loop more extensively than BIM1, suggesting that differential loop engagement contributes to inhibitor selectivity. To probe how gating reshapes this region, we solved the structure in the presence of Ca

Indexed as

channel gatingCLC-Ka chloride channelcryo-EMisoform selectivityMajor: Biological SciencesMinor: Biophysics and Computational Biologymolecular dynamics simulations

Identifiers

PMID41756880
PMCPMC12934935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.